Minocycline hydrochloride
Based on 76 publication(s) in Google Scholar
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.71%
- CAS No.: 13614-98-7
- Formule: C23H28ClN3O7
- Masse moléculaire:493.94
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B2060A
Tiamulin fumarateAntibiotic -
HY-B0117
TigecyclineBacterial Inhibitor -
HY-N0565
DoxycyclineMMP Inhibitor -
HY-A0107
TetracyclineAntibiotic -
HY-N0565B
Doxycycline hyclateMMP Inhibitor -
HY-107647
(S)-(+)-Dimethindene maleateM2 Receptor Antagonist -
HY-17412R
Minocycline hydrochloride (Standard)HIF-1α/Glutamate Inhibitor -
HY-A0276
Gentamicin sulfateAminoglycoside Antibiotic -
HY-13678
MeropenemAntimicrobial Agent -
HY-10394
LinezolidAntibiotic -
HY-B1327
Chlortetracycline hydrochlorideCalcium Ionophore Antibiotic, Methanogenic Bacteria Inhibitor -
HY-B0509A
AmikacinAntibiotic
Publications Citing Use of MedChemExpress (MCE) Minocycline hydrochloride
More- Cell Stem Cell. 2025 Oct 2;32(10):1509-1527.e9. [Abstract]
- Nat Neurosci. 2025 Jul;28(7):1404-1417. [Abstract]
- Adv Funct Mater. 2023 Jul 7.
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Theranostics. 2020 Jan 1;10(1):74-90. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(11):e2412556. [Abstract]
- Research (Wash D C). 2025 Sep 25:2025:0897. [Abstract]
- Pharmacol Res. 2023 May:191:106773. [Abstract]
- J Neuroinflammation. 2025 Oct 28;22(1):249. [Abstract]
- J Neuroinflammation. 2018 Aug 30;15(1):245. [Abstract]
- Phytomedicine. 2023 May:113:154725. [Abstract]
- J Hazard Mater Adv. 2025 Nov 12;20:100939.
- J Headache Pain. 2026 Feb 9;27(1):39. [Abstract]
- Mol Med. 2025 Apr 24;31(1):153. [Abstract]
- J Genet Genomics. 2024 Mar;51(3):338-351. [Abstract]
- Cell Rep. 2025 Dec 10;44(12):116671. [Abstract]
- Brain Behav Immun. 2026 Jul 6:138:106890.
- Transl Psychiatry. 2025 Aug 15;15(1):285. [Abstract]
- Brain Behav Immun. 2025 Jun 25:129:649-661. [Abstract]
- Brain Behav Immun. 2021 Jan:91:519-530. [Abstract]
- Brain Behav Immun. 2021 Jan:91:505-518. [Abstract]
- Brain Behav Immun. 2020 Oct:89:400-413. [Abstract]
- Fundam Res. 2023 Jul 16;4(4):806-819. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- J Ethnopharmacol. 2025 Mar 26:344:119459. [Abstract]
- CNS Neurosci Ther. 2026 Feb;32(2):e70795. [Abstract]
- Cell Biosci. 2024 Apr 16;14(1):48. [Abstract]
- Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]
- J Neuroimmune Pharmacol. 2024 May 22;19(1):23. [Abstract]
- J Clin Microbiol. 2025 Feb 19;63(2):e0148024. [Abstract]
- Cell Rep Methods. 2024 Sep 16;4(9):100843. [Abstract]
- J Dent. 2023 Sep:136:104624. [Abstract]
- J Affect Disord. 2026 Jun 15:403:121439. [Abstract]
- Eur J Pharmacol. 2024 Sep 5:978:176763. [Abstract]
- Int J Mol Sci. 2026 May 26;27(11):4798. [Abstract]
- Int Immunopharmacol. 2026 Mar 15:173:116327. [Abstract]
- Int Immunopharmacol. 2025 Oct 30:164:115351. [Abstract]
- Int Immunopharmacol. 2025 Aug 28:161:115034. [Abstract]
- Int Immunopharmacol. 2024 Nov 3;143(Pt 3):113538. [Abstract]
- Int Immunopharmacol. 2023 Jul:120:110347. [Abstract]
- Mol Neurobiol. 2021 Oct;58(10):4828-4841. [Abstract]
- J Pathol. 2026 Jan;268(1):99-112. [Abstract]
- Chem Biol Interact. 2026 Jul 25:435:112153. [Abstract]
- ACS Omega. 2022 Mar 3;7(10):9004-9014. [Abstract]
- Int J Antimicrob Agents. 2018 Aug;52(2):269-271. [Abstract]
- Neuropharmacology. 2020 Jun 15:170:108054. [Abstract]
- Neuropharmacology. 2018 Jun:135:223-233. [Abstract]
- J Inflamm Res. 2026 Apr 17:19:592917. [Abstract]
- Neurochem Res. 2026 Jun 29;51(4):205.
- iScience. 2022 Jan 5;25(2):103731. [Abstract]
- Neurochem Res. 2017 Oct;42(10):2698-2711. [Abstract]
- Ann Lab Med. 2021 May 1;41(3):293-301. [Abstract]
- Neuroprotection. 2026 Jul 19:10.1002/nep3.70044.
- Microbiol Spectr. 2026 Mar 30;14(5):e0147325. [Abstract]
- J Clust Sci. 2025 Nov 16;36(6):229.
- Microbiol Spectr. 2025 May 6;13(5):e0318524. [Abstract]
- Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611. [Abstract]
- Toxicol Appl Pharmacol. 2024 Mar:484:116859. [Abstract]
- Brain Sci. 2023 Mar 19;13(3):512. [Abstract]
- Biochem Biophys Rep. 2026 Jul 18:47:102718.
- Infect Drug Resist. 2026 May 8;19.
- Food Chem Toxicol. 2023 Apr:174:113692. [Abstract]
- Genes (Basel). 2024 Oct 30;15(11):1400. [Abstract]
- Behav Brain Res. 2024 Mar 12:461:114843. [Abstract]
- PLoS One. 2025 Jan 31;20(1):e0315714. [Abstract]
- Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. [Abstract]
- J Mol Neurosci. 2025 Aug 2;75(3):97. [Abstract]
- Comput Methods Biomech Biomed Engin. 2025 Dec 10:1-16. [Abstract]
- bioRxiv. 2026 May 7.
- SSRN. 2026 Apr 7.
- Res Sq. 2026 Mar 9.
- Research Square Preprint. 2024 Mar 6.
- bioRxiv. 2023 Dec 20.
- Research Square Preprint. 2022 Feb.
- Oxid Med Cell Longev. 2021 Nov 5:2021:6715758. [Abstract]
- Research Square Preprint. 2020 Jun.
Customer Validation & Images
-
IF
-
WB
-
IHC
-
ELISA
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
Description
IC50 & Target
|
L-type calcium channel |
In Vitro
Minocycline hydrochloride (0-100 μM, 24-72 h) suppresses proliferation and clonogenic activity of ovarian cancer cell-lines (OVCAR-3, SKOV-3 and A2780)[3].
Minocycline hydrochloride (0-100 μM, 24-48 h)arrests cell cycle through inhibition of cyclins and suppression of DNA incorporation[3].
Minocycline hydrochloride (0-100 μM, 72 h) induces cell apoptosis in ovarian cancer cell lines[3].
Minocycline hydrochloride shows direct neuronal protection, and this mode of protection is likely to be associated with the preservation of mitochondrial integrity and cytochrome c, followed by the suppression of caspase-dependent as well as caspase-independent cell death[2].
Minocycline hydrochloride leads to suppression of Hypoxia-inducible factor (HIF)-1α accompanied by up-regulation of p53 protein levels and inactivation of AKT/mTOR/p70S6K/4E-BP1 pathway[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human ovarian cancer cell lines (OVCAR-3, SKOV-3 and A2780) and primary cells (HEK-293, HMEC, HUVEC, ATCC)
-
Concentration:0, 1, 10, 50 and 100 μM
-
Incubation Time:24, 48 or 72 h
-
Result:Inhibited proliferation of OVCAR-3, SKOV-3 and A2780 cells in a concentration-dependent manner, with IC50 values of 62.0, 56.1 and 59.5 μM, respectively. Had no effect on the viability of HEK-293 or HUVEC.
-
Cell Line:OVCAR-3, SKOV-3 and A2780 cells
-
Concentration:0, 10, 50 and 100 μM
-
Incubation Time:72 h
-
Result:Expressed lower levels of cyclins A, B and E. Increased caspase-3 levels by more than 3.0 fold in the 100 μM. Minocycline-activated caspase-3 in turn led to cleavage of PARP-1. Increased the degradation product p89 of PARP-1 by caspase-3.
-
Cell Line:OVCAR-3, SKOV-3 and A2780 cells
-
Concentration:0, 10, 50 and 100 μM
-
Incubation Time:24 or 48 h
-
Result:Arrested cells in the G0-G1 phase in a concentration and time-dependent manner. Declined percentage of cells in the S and G2-M phases in excess of 80% each at 100 μM.
In Vivo
Minocycline hydrochloride (IP) is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally[1].
Minocycline hydrochloride (0-40 mg/kg, IP, once) significantly attenuats METH-induced hyperlocomotion and the development of behavioral sensitization in mice[2].
Minocycline hydrochloride (3 and 10 mg/kg, IV, once) is effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO)[1].
Minocycline hydrochloride (3-10 mg/kg, IV, once) results in serum levels (at 3 mg/kg) similar to that achieved in humans after a standard 200 mg dose[1].
Minocycline hydrochloride attenuates ischemia-induced ventricular arrhythmias in rats. This effect may be associated with activations of PI3K/Akt signaling pathway, mitochondrial KATP channels and L-type Ca2+ channels[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude mice (6 weeks old, 9 per group, OVCAR-3 cells were injected s.c. into the left flank of each mouse)[3]
-
Dosage:10 or 30 mg/kg
-
Administration:Administered orally in the drinking water, initiated on day 8 of cell inoculation, daily for 4 weeks
-
Result:Suppressed OVCAR-3 tumor growth in these female nude mice, and reduced microvessel density.
-
Animal Model:Male Balb/cAnNCrICrIj mice (8 weeks old, 23-30 g, methamphetamine (METH, 3 mg/kg) was injected subcutaneously (s.c.) in a volume of 10 ml/kg)[2]
-
Dosage:0, 10, 20, or 40 mg/kg
-
Administration:IP, once, 30 min before the administration of METH
-
Result:Significantly attenuated METH-induced hyperlocomotion and the development of behavioral sensitization in mice at 40 mg/kg. Did not exert any effect on the induction of METH-induced hyperthermia in mice. Significantly attenuated the reduction of DA and DOPAC in the striatum. Significantly attenuated the reduction of DAT-immunoreactivity in the mouse striatum. Significantly attenuated the increase in MAC1-immunoreactivity in the striatum after the administration of METH.
-
Animal Model:Male Sprague-Dawley rats (270-330 g, TMCAO model)[1]
-
Dosage:3 mg/kg and 10 mg/kg
-
Administration:IV, once, 4, 5, or 6 hours post TMCAO
-
Result:Reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56% at doses of 3 mg/kg; significantly reduced infarct size at 5 hours by 40% at doses of 10 mg/kg and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction.
-
Animal Model:Male Sprague-Dawley rats (270-330 g)[1]
-
Dosage:3, 10, or 20 mg/kg
-
Administration:IV, once
-
Result:Peak concentrations of serum levels of minocycline averaged 3.6, 13.0 and 28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The serum levels of minocycline at a 3 mg/kg dose (3.6 mg/L) were similar to that reported in humans after a standard 200 mg dose. Did not significantly affect hemodynamic and physiological variables.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 13614-98-7
-
Appearance Solid
-
Masse moléculaire 493.94
-
Formule C23H28ClN3O7
-
Color Yellow to brown
-
SMILES
OC1=C(C(N)=O)C([C@@]2(O)C(O)=C3C(C4=C(O)C=CC(N(C)C)=C4C[C@@]3([H])C[C@@]2([H])[C@@H]1N(C)C)=O)=O.Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (76)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
An inducible model of human post-implantation development derived from primed and naive stem cells. [Abstract]2025 Oct 2;32(10):1509-1527.e9. PMID: 40885193 -
Nat Neurosci
GABA-dependent microglial elimination of inhibitory synapses underlies neuronal hyperexcitability in epilepsy. [Abstract]2025 Jul;28(7):1404-1417. PMID: 40425792 -
-
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Theranostics
Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion. [Abstract]2020 Jan 1;10(1):74-90. PMID: 31903107 -
Adv Sci (Weinh)
Microglia-Derived Interleukin-6 Triggers Astrocyte Apoptosis in the Hippocampus and Mediates Depression-Like Behavior. [Abstract]2025 Mar;12(11):e2412556. PMID: 39888279
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(11):e2412556. [Abstract]
Representative images of Iba1 (green) and IL-6 (red) staining in the hippocampus of Con and CSDS mice treated with Minocycline (Mino) (40 nM, 250 nL/side) or aCSF via an infusion cannula.
-
Research (Wash D C)
Interleukin-4-Mediated NLRP3 Inflammasome Activation in Microglia Contributes to Allergic Rhinitis via Central Sensitization. [Abstract]2025 Sep 25:2025:0897. PMID: 41019284 -
Pharmacol Res
Proinflammatory activation of microglia in the cerebellum hyperexcites Purkinje cells to trigger ataxia. [Abstract]2023 May:191:106773. PMID: 37068531 -
J Neuroinflammation
The activation of hippocampus microglia in the occurrence of airway hyperresponsiveness comorbidity anxiety. [Abstract]2025 Oct 28;22(1):249. PMID: 41152897 -
J Neuroinflammation
Microglia P2X4 receptor contributes to central sensitization following recurrent nitroglycerin stimulation. [Abstract]2018 Aug 30;15(1):245. PMID: 30165876
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2018 Aug 30;15(1):245. [Abstract]
Immunostaining of the trigeminal nucleus caudalis (TNC) for Iba1 in the NTG group and the NTG+Minocycline (Mino) group on day 9.
-
Phytomedicine
Gastrodin programs an Arg-1+ microglial phenotype in hippocampus to ameliorate depression- and anxiety-like behaviors via the Nrf2 pathway in mice. [Abstract]2023 May:113:154725. PMID: 36867963 -
-
J Headache Pain
Downregulation of neuronal DRD2 drives microglia synaptic pruning and results in cognitive deficits by promoting CCL2 release in a rat model of chronic migraine. [Abstract]2026 Feb 9;27(1):39. PMID: 41663919 -
Mol Med
Formononetin ameliorates depression-like behaviors through rebalancing microglia M1/M2 polarization and inhibiting NLRP3 inflammasome: involvement of activating PPARα-mediated autophagy. [Abstract]2025 Apr 24;31(1):153. PMID: 40275171
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Med. 2025 Apr 24;31(1):153. [Abstract]
BV2 cells were pre-treated with FMN (30 µM), chloroquine (CQ, 20 µM) and minocycline (Mino, 20 µM) for 1 h and then incubated with LPS (1 µg/mL) for 24 h, quantification of protein expression levels of CD68, CD206 and NLRP3.
-
J Genet Genomics
2024 Mar;51(3):338-351. PMID: 37703921 -
Cell Rep
Microglial macrophage-derived ds-HMGB1 in DRG orchestrates neuropathic pain through immune-neural signaling. [Abstract]2025 Dec 10;44(12):116671. PMID: 41385369 -
-
Transl Psychiatry
Microglia-mediated inflammation and synaptic pruning contribute to sleep deprivation-induced mania in a sex-specific manner. [Abstract]2025 Aug 15;15(1):285. PMID: 40817224 -
Brain Behav Immun
Microglia-mediated neurogenesis is linked to cognitive deficits in a two-hit model of maternal immune activation and juvenile stress. [Abstract]2025 Jun 25:129:649-661. PMID: 40578538 -
Brain Behav Immun
Minocycline alleviates depression-like symptoms by rescuing decrease in neurogenesis in dorsal hippocampus via blocking microglia activation/phagocytosis. [Abstract]2021 Jan:91:519-530. PMID: 33176182 -
Brain Behav Immun
Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. [Abstract]2021 Jan:91:505-518. PMID: 33161163 -
Brain Behav Immun
Suppression of microglial activation and monocyte infiltration ameliorates cerebellar hemorrhage induced-brain injury and ataxia. [Abstract]2020 Oct:89:400-413. PMID: 32717406 -
Fundam Res
Activation and polarization of striatal microglia and astrocytes are involved in bradykinesia and allodynia in early-stage parkinsonian mice. [Abstract]2023 Jul 16;4(4):806-819. PMID: 39156564 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
J Ethnopharmacol
Ditan Decoction ameliorates vascular dementia-induced cognitive dysfunction through anti-ferroptosis via the HIF1α pathway: Integrating network pharmacology and experimental validation. [Abstract]2025 Mar 26:344:119459. PMID: 39978449 -
CNS Neurosci Ther
KCC2 Dysfunction Mediated by Microglial BDNF/TrkB Signaling Exacerbates Early Post-Stroke Seizure Susceptibility. [Abstract]2026 Feb;32(2):e70795. PMID: 41689206 -
Cell Biosci
GLUT1-mediated microglial proinflammatory activation contributes to the development of stress-induced spatial learning and memory dysfunction in mice. [Abstract]2024 Apr 16;14(1):48. PMID: 38627830 -
Inflamm Res
Minocycline alleviates microglia ferroptosis by inhibiting HO-1 during cerebral ischemia-reperfusion injury. [Abstract]2024 Oct;73(10):1727-1745. PMID: 39112649
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]
Minocycline (80 μM)-treated MCAO/R group was signifcantly higher than that in the MCAO/R groups.
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]
ELISA results showed that Minocycline (80 μM) reduced the concentrations of TNF-α and IL-1β, and increased the concentrations of IL-4 and IL-10.
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2024 Oct;73(10):1727-1745. [Abstract]
BV-2 cells were incubated with Minocycline (80 μM) followed by OGD/R treatment for 8 h, the LDH release assay showed cell damage.
-
J Neuroimmune Pharmacol
Inhibition of Microglial Activation Ameliorates Inflammation, Reduced Neurogenesis in the hippocampus, and Impaired Brain Function in a Rat Model of Bilirubin Encephalopathy. [Abstract]2024 May 22;19(1):23. PMID: 38775885 -
J Clin Microbiol
Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis. [Abstract]2025 Feb 19;63(2):e0148024. PMID: 39840992 -
Cell Rep Methods
2024 Sep 16;4(9):100843. PMID: 39216483 -
J Dent
Calcium phosphate cement with minocycline hydrochloride-loaded gelatine microspheres for peri-implantitis treatment. [Abstract]2023 Sep:136:104624. PMID: 37459952 -
J Affect Disord
Ketamine ameliorates postpartum depression-like behaviors in rats exposed to sevoflurane during pregnancy through the AMPK/SIRT1/NLRP3 pathway. [Abstract]2026 Jun 15:403:121439. PMID: 41698615 -
Eur J Pharmacol
Apoptosis-induced decline in hippocampal microglia mediates the development of depression-like behaviors in adult mice triggered by unpredictable stress during adolescence. [Abstract]2024 Sep 5:978:176763. PMID: 38906239 -
Int J Mol Sci
PSMB4/MHC-I Signaling in the Cerebrospinal Fluid-Contacting Nucleus Mediates Neuroinflammatory Depression in Mice. [Abstract]2026 May 26;27(11):4798. PMID: 42278327 -
Int Immunopharmacol
BDNF and NLRP3 signaling differentially regulate formation and retrieval of nitrous oxide (N2O)-related rewarding memory in dorsal hippocampus CA3 region. [Abstract]2026 Mar 15:173:116327. PMID: 41662814 -
Int Immunopharmacol
Paeoniflorin attenuates neuropathic Pain-associated depression by modulating microglial M1 polarization and correcting kynurenine pathway dysregulation. [Abstract]2025 Oct 30:164:115351. PMID: 40803216 -
Int Immunopharmacol
IRF8-Cathepsin S/PAR2 axis-mediated spinal microglia-neuron crosstalk is responsible for the exacerbation of postsurgical pain induced by preoperative stress. [Abstract]2025 Aug 28:161:115034. PMID: 40482455 -
Int Immunopharmacol
Kaempferol improves depression-like behaviors through shifting microglia polarization and suppressing NLRP3 via tilting the balance of PPARγ and STAT1 signaling. [Abstract]2024 Nov 3;143(Pt 3):113538. PMID: 39492132 -
Int Immunopharmacol
Intranasal administration of lipopolysaccharide reverses chronic stress-induced depression-like behavior in mice by microglial stimulation. [Abstract]2023 Jul:120:110347. PMID: 37270930 -
Mol Neurobiol
Gut-Derived Exosomes Mediate Memory Impairment After Intestinal Ischemia/Reperfusion via Activating Microglia. [Abstract]2021 Oct;58(10):4828-4841. PMID: 34189701 -
J Pathol
Hypoxia-induced regional heterogeneity in proliferative vitreoretinopathy: implications for targeted therapies. [Abstract]2026 Jan;268(1):99-112. PMID: 41215615 -
Chem Biol Interact
A combined in silico and in vitro new approach methodology for early detection of liver steatogenic chemicals. [Abstract]2026 Jul 25:435:112153. PMID: 42173389 -
ACS Omega
Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]2022 Mar 3;7(10):9004-9014. PMID: 35309438 -
Int J Antimicrob Agents
Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]2018 Aug;52(2):269-271. PMID: 29559273 -
Neuropharmacology
Apoptosis-triggered decline in hippocampal microglia mediates adolescent intermittent alcohol exposure-induced depression-like behaviors in mice. [Abstract]2020 Jun 15:170:108054. PMID: 32217088 -
Neuropharmacology
Dynamic changes in hippocampal microglia contribute to depressive-like behavior induced by early social isolation. [Abstract]2018 Jun:135:223-233. PMID: 29574097 -
J Inflamm Res
Acupuncture Activates PI3K/Akt Pathway to Promote Spinal Microglial M2 Polarization and Alleviate Spastic Hemiplegia Following Ischemic Stroke. [Abstract]2026 Apr 17:19:592917. PMID: 42022268 -
-
iScience
2022 Jan 5;25(2):103731. PMID: 35098100 -
Neurochem Res
Microglia Loss Contributes to the Development of Major Depression Induced by Different Types of Chronic Stresses. [Abstract]2017 Oct;42(10):2698-2711. PMID: 28434164
Minocycline hydrochloride purchased from MedChemExpress. Usage Cited in: Neurochem Res. 2017 Oct;42(10):2698-2711. [Abstract]
a Statistical analysis showing the prevention effect of minocycline pretreatment (40 mg/kg/day) on CUS-, CRS- or CSDS-induced decreases in hippocampal microglial numbers. b, c Statistical analysis showing the prevention effect of Minocycline pretreatment (40 mg/kg/day) on CUS-, CRS- or CSDS-induced increases in the immobile time in the TST (b) and FST (c).
-
Ann Lab Med
In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. [Abstract]2021 May 1;41(3):293-301. PMID: 33303714 -
-
Microbiol Spectr
Eravacycline for Mycobacterium abscessus infections: pharmacodynamic advantages of long-acting post-antibiotic effects and weekly dosing regimens. [Abstract]2026 Mar 30;14(5):e0147325. PMID: 41910138 -
-
Microbiol Spectr
Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistant Candida tropicalis. [Abstract]2025 May 6;13(5):e0318524. PMID: 40162832 -
Open Forum Infect Dis
Successful Treatment of Recurrent Extensively Drug-Resistant Elizabethkingia anophelis Bacteremia Secondary to Ventricular Assist Device-Associated Infection. [Abstract]2024 Oct 11;11(11):ofae611. PMID: 39494452 -
Toxicol Appl Pharmacol
Minocycline attenuates the bilirubin-induced developmental neurotoxicity through the regulation of innate immunity and oxidative stress in zebrafish embryos. [Abstract]2024 Mar:484:116859. PMID: 38342443 -
Brain Sci
Minocycline Attenuates Sevoflurane-Induced Postoperative Cognitive Dysfunction in Aged Mice by Suppressing Hippocampal Apoptosis and the Notch Signaling Pathway-Mediated Neuroinflammation. [Abstract]2023 Mar 19;13(3):512. PMID: 36979321 -
-
-
Food Chem Toxicol
Inactivation of microglia dampens blood-brain barrier permeability and loss of dopaminergic neurons in paraquat-lesioned mice. [Abstract]2023 Apr:174:113692. PMID: 36842752 -
Genes (Basel)
Influence and Optimization of Diverse Culture Systems on Chicken Embryonic Stem Cell Culture. [Abstract]2024 Oct 30;15(11):1400. PMID: 39596599 -
Behav Brain Res
MHC-I in the hippocampus promotes comorbid depressive symptoms in bone cancer pain via the upregulation of microglial TREM2/DAP12 signaling. [Abstract]2024 Mar 12:461:114843. PMID: 38176616 -
PLoS One
Peptidoglycan recognition protein PGRP-5 is involved in immune defence and neuro-behavioral disorders in zebrafish embryos. [Abstract]2025 Jan 31;20(1):e0315714. PMID: 39888929 -
Clin Exp Pharmacol Physiol
In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. [Abstract]2023 Jul;50(7):604-609. PMID: 37086075 -
J Mol Neurosci
Gamma Oscillation Disruption Induced By Microglial Activation Contributes to Perioperative Neurocognitive Disorders in Aged Mice. [Abstract]2025 Aug 2;75(3):97. PMID: 40753364 -
Comput Methods Biomech Biomed Engin
Developing a diagnostic model for necroptosis in osteoporosis using bioinformatics and machine learning. [Abstract]2025 Dec 10:1-16. PMID: 41370854 -
-
-
-
-
-
-
Oxid Med Cell Longev
mTORC1 Activation in Chx10-Specific Tsc1 Knockout Mice Accelerates Retina Aging and Degeneration. [Abstract]2021 Nov 5:2021:6715758. PMID: 34777691 -
Solvant et solubilité
In Vitro:
DMSO : 19.23 mg/mL (38.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 9.09 mg/mL (18.40 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 7.69 mg/mL (15.57 mM); Clear solution; Need ultrasonic
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (290 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Xu L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7. [Content Brief]
[2]. Zhang L, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93. [Content Brief]
[3]. Pourgholami MH, et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125(2):433-40. [Content Brief]
[4]. Molina-Hernández M, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6. [Content Brief]
[5]. Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80. [Content Brief]
[6]. Ataie-Kachoie P, et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5(2):575-88. [Content Brief]
[7]. Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654(3):274-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.0245 mL | 10.1227 mL | 20.2454 mL | 50.6134 mL |
| 5 mM | 0.4049 mL | 2.0245 mL | 4.0491 mL | 10.1227 mL | |
| 10 mM | 0.2025 mL | 1.0123 mL | 2.0245 mL | 5.0613 mL | |
| 15 mM | 0.1350 mL | 0.6748 mL | 1.3497 mL | 3.3742 mL | |
| DMSO | 20 mM | 0.1012 mL | 0.5061 mL | 1.0123 mL | 2.5307 mL |
| 25 mM | 0.0810 mL | 0.4049 mL | 0.8098 mL | 2.0245 mL | |
| 30 mM | 0.0675 mL | 0.3374 mL | 0.6748 mL | 1.6871 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Minocycline hydrochloride Related Classifications
HY-17412 Related Classifications
Powered by Bioz
Keywords
- Minocycline
- 13614-98-7
- Bacterial
- Antibiotic
- HIF/HIF Prolyl-Hydroxylase
- Apoptosis
- MDM-2/p53
- Potassium Channel
- Calcium Channel
- cerebral ischemia
- neuroprotective
- stroke
- Ventricular arrhythmia
- Myocardial ischemia
- PI3K/Akt
- Mitochondrial ATP-sensitive potassium
- L-type Ca2+ channel
- acinetobacter
- infection
- ovarian cancer
- Inhibitor
- inhibitor
- inhibit